A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 401–500 of 1,002
Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline
Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 57
Fan, L., Qiu, X., Zhu, Z., Lv, J., Lu, J., Mao, F., Zhu, J., Wang, J., Guan, X., Chen, J., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0220-1 · Cited by 47
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
Doody, R. S., Raman, R., Sperling, R. A., Seimers, E., Sethuraman, G., Mohs, R., Farlow, M., Iwatsubo, T., Vellas, B., Sun, X., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0121-6 · Cited by 43
“Additional details regarding methods are provided in the Appendix to the article describing the primary results of the phase III trial [10].”
BackgroundMethodInfluentialSelf-citationAyton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 52
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
“144 Several clinical trials with γ -secretase inhibitors, such as semagacestat, 145 avagacestat, and tarenflurbil, have shown limited efficacy and significant safety concerns.”
Ascher‐Svanum, H., Chen, Y.-F., Hake, A. M., Kahle‐Wrobleski, K., Schuster, D., Kendall, D. M., & Heine, R. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.002 · Cited by 48
“These analyses were repeated on data from patients with moderate AD.”
MethodInfluentialC-Terminal Fragment, Aβ32–37, Analogues Protect Against Aβ Aggregation-Induced Toxicity
Bansal, S., Maurya, I. K., Yadav, N., Thota, C. K., Kumar, V., Tikoo, K., Chauhan, V. S., & Jain, R. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00006 · Cited by 48
Pine, S. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1635 · Cited by 45
“The first GSI to enter Phase III clinical trials for Alzheimer’s disease was not only ineffective, it accelerated cognitive decline, even though the GSI decreased β-amyloid levels in a dose-dependent manner [14].”
BackgroundKnockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities
Gabriele, R. M. C., Abel, E., Fox, N. C., Wray, S., & Arber, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.835645 · Cited by 44
Biflavonoids as Potential Small Molecule Therapeutics for Alzheimer’s Disease
Thapa, A., & Chi, E. Y. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18365-7_3 · Cited by 45
“clinical trial (Nie et al. 2011; Doody et al. 2013).”
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C., Carrillo, M. C., Bain, L. J., DeMattos, R., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
Self-citationMandal, M., Wu, Y., Misiaszek, J., Li, G., Buevich, A. V., Caldwell, J. P., Liu, X., Mazzola, R., Orth, P., Strickland, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01995 · Cited by 45
Physiological functions of SPP/SPPL intramembrane proteases
Mentrup, T., Cabrera-Cabrera, F., Fluhrer, R., & Schröder, B. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03470-6 · Cited by 46
Successive cleavage of β-amyloid precursor protein by γ-secretase
Funamoto, S., Tagami, S., Okochi, M., & Morishima‐Kawashima, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.002 · Cited by 48
Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
Nordvall, G., Lundkvist, J., & Sandin, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1279740 · Cited by 44
“Inhibitors of gamma-secretase (GSIs) produced robust A β lowering in animals and were tested in clinical trials (Semagacestat Phase 3, Avagacestat Phase 2) (Doody et al., 2013; Coric et al., 2015).”
MethodZhang, M., Wang, W., Ye, Q., Fu, Y., Li, X., Yang, K., Gao, F., Zhou, A., Wei, Y., Tian, S., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01384-0 · Cited by 44
“Due to toxicity and futility, clinical trials for β-secretase inhibitors (Verubecestat [39], Atabecestat [40]) and γ-secretase inhibitors (Semagacestat [41], Ava-gacestat [42]) were halted [43].”
BackgroundDesign, data monitoring, and analysis of clinical trials with co-primary endpoints: A review
Hamasaki, T., Evans, S. R., & Asakura, K. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1378668 · Cited by 43
“For example, Doody et al. (2013) reported a randomized controlled clinical trial to evaluate an effect of semagacestat 100 mg and 140 mg compared with placebo in patients with probable Alzheimer’s disease, and 19 countries participated in the trial.”
BackgroundWessels, A. M., Dowsett, S. A., & Sims, J. R. (2018) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.2 · Cited by 39
“Semagacestat Doody 2013 (36) IDENTITY 2 1537 16-26 11 76”
Reactions at Biomembrane Interfaces
Bondar, A., & Lemieux, M. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00596 · Cited by 46
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 44
Moncunill, G., Rosa, S. C. D., Ayestaran, A., Nhabomba, A. J., Mpina, M., Cohen, K. W., Jairoce, C., Rutishauser, T., Campo, J. J., Harezlak, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01008 · Cited by 46
“These models are commonly used (21–24) and allow to model jointly the different cell stimulations that each subject sample underwent using random effects.”
BackgroundPenninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160275 · Cited by 42
Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease
Prvulovic, D., & Schneider, B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.915028 · Cited by 45
“Recent disappointing examples include semagacestat [14], dimebon [15] and the anti-amyloid antibody drugs bapineuzumab and solanezumab [16].”
BackgroundConsidering a new paradigm for Alzheimer's disease research
Langley, G. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.013 · Cited by 42
“[84,85]”
Deatherage, C. L., Lu, Z., Kroncke, B. M., Ma, S., Smith, J. A., Voehler, M., McFeeters, R. L., & Sanders, C. R. (2017) · Science Advances · doi:10.1126/sciadv.1602794 · Cited by 43
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 48
Self-citationKöseoğlu, M. M., Norambuena, A., Sharlow, E. R., Lazo, J. S., & Bloom, G. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180874 · Cited by 45
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
Panza, F., Lozupone, M., Watling, M., & Imbimbo, B. P. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621751 · Cited by 41
“γ-secretase inhibitor) was reported in a Phase III trial involving 1,537 mild-to-moderate AD patients [15].”
BackgroundPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 45
Wang, J., Lei, X., Cheng, X., Zhang, X., Liu, G., Cheng, J., Xu, Y., Ju, Z., Zhou, W., & Zhang, Y. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0226-6 · Cited by 42
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease
Pons, V., & Rivest, S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000400 · Cited by 43
Faronato, M., Nguyen, V. T. M., Patten, D. K., Lombardo, Y., Steel, J. H., Patel, N. R., Woodley, L., Shousha, S., Pruneri, G., Coombes, R. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4164 · Cited by 44
“At the moment, the approach taken to target Notch signalling had been through the use of GSIs that inhibit signalling by all four Notch receptors [52, 53].”
BackgroundEndosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology
Arbo, B. D., Cechinel, L. R., Palazzo, R. P., & Siqueira, I. R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101006 · Cited by 38
Zhang, Q., Zhao, W., Hou, Y., Song, X., Yu, H., Tan, J., Zhou, Y., & Zhang, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14132 · Cited by 40
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 44
“Another frequently used case against the role of A b in AD is the disappointing results from clinical trials aiming to reduce A b load. c -Secretase inhibitors have been unsuccessful in combatting the cognitive decline of AD [25,26].”
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 40
Intramembrane proteases as drug targets
Verhelst, S. H. L. (2017) · FEBS Journal · doi:10.1111/febs.13979 · Cited by 45
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Bazzari, F. H., Abdallah, D. M., & El-Abhar, H. S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190301111120 · Cited by 42
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 43
Ahn, J. E., Carrieri, C., Dela Cruz, F., Fullerton, T., Hajos‐Korcsok, E., He, P., Kantaridis, C., Leurent, C., Liu, R., Mancuso, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1570 · Cited by 36
Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease
Feustel, A. C., MacPherson, A., Fergusson, D. A., Kieburtz, K. D., & Kimmelman, J. (2019) · Neurology · doi:10.1212/wnl.0000000000008699 · Cited by 40
“Moreover, some putatively diseasemodifying treatments have presented safety issues.(7,8) Nevertheless, small but statistically insignificant benefit associated with treatment assignment, when aggregated across trials, might add up to an overall advantage.”
BackgroundSelf-citationBullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“In the crenezumab trials, inclusion criteria in the phase II ABBY and BLAZE studies required participants to have a CDR-SB score ≥ 0.5 and MMSE of 18–26 points (Cummings, Cohen, et al., 2018; Salloway et al., 2018).”
InfluentialSelf-citationTherapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Recent Advances: Decoding Alzheimer’s Disease With Stem Cells
Fang, Y., Gao, T., Zhang, B., & Pu, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00077 · Cited by 42
“Recently, several pioneering spotlighted trials targeting Aβ have met with dissatisfying results in terms of improved cognitive function (Doody et al., 2013; Salloway et al., 2014).”
BackgroundInsulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 42
“-secretase, which ended up worsening the cognitive impairment and increasing skin cancers and infections cases [55, 56].”
Akhter, H., Ballinger, C., Liu, N., van Groen, T., Postlethwait, E. M., & Liu, R.-M. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv124 · Cited by 37
Huang, Y., Guimarães, T. R., Todd, N., Ferguson, C., Weiss, K. M., Stauffer, F., McDermott, B., Hurtle, B. T., Saito, T., Saido, T. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204828119 · Cited by 38
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
“Notwithstanding the absence of cognitive benefit, a significant increase in CSF total Aβ42 was observed with semagacestat (Doody et al., 2013).”
BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines
Blume, T., Filser, S., Jaworska, A., Blain, J.-F., Koenig, G., Moschke, K., Lichtenthaler, S. F., & Herms, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00229 · Cited by 36
“Prolonged treatment with LY-450139 caused worsening of cognitive functions in AD patients as well as infections and skin cancer (Schor, 2011) leading to early termination of the study in clinical phase III, April 2011 (Doody et al., 2013).”
BackgroundMonocytes in the Peripheral Clearance of Amyloid-β and Alzheimer’s Disease
Guo, H., Zhao, Z., Zhang, R., Chen, P., Zhang, X., Cheng, F., & Gou, X. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181177 · Cited by 36
“The accumulation of the toxic protein amyloid-(cid:2) (A (cid:2) ) in the brain is the most frequently hypothesized initiating factor of AD; however, some drugs targeting A (cid:2) have been unsuccessful in clinical trials, possibly because the intervention was given too late [5, 6].”
Li, X., Lu, J., Xu, Y., Wang, J., Qiu, X., Fan, L., Li, B., Liu, W., Mao, F., Zhu, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.006 · Cited by 40
“4-Chloro-2-hydroxy-N-(5-morpholinothiazol-2-yl) benzamide (16) 16 was synthesized by the general procedure of 15 given above, 4fluoro-2-hydroxybenzoic acid was replaced by 4-choro-2hydroxybenzoic acid, to afford 16 as a yellow solid.”
MethodCurrent druggable targets for therapeutic control of Alzheimer's disease
Gupta, G. L., & Samant, N. P. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106549 · Cited by 41
Novel lipid signaling pathways in Alzheimer's disease pathogenesis
Giannopoulos, P. F., Joshi, Y. B., & Praticò, D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.005 · Cited by 39
Walsh, C., Drinkenburg, W. H. I. M., & Ahnaou, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.020 · Cited by 39
Sun, Y., Islam, S., Michikawa, M., & Zou, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031757 · Cited by 40
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
Weissmiller, A. M., Natera-Naranjo, O., Reyna, S. M., Pearn, M. L., Zhao, X., Nguyen, P., Cheng, S., Goldstein, L. S. B., Tanzi, R. E., Wagner, S. L., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118379 · Cited by 39
“Whether or not this played a role in the failure of GSI Phase III clinical trials for treatment of AD [7, 8, 63], or for GSI-induced changes in cognition in animal models is uncertain [42, 46, 70, 71].”
BackgroundInfluentialAberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Therapeutic strategies for targeting neurodegenerative protein misfolding disorders
Scannevin, R. H. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.018 · Cited by 40
Guo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 39
Foroutan, N., Hopkins, R. B., Tarride, J., Flórez, I. D., & Levine, M. (2019) · Clinical and investigative medicine · doi:10.25011/cim.v42i1.32393 · Cited by 38
Nie, P., Vartak, A., & Li, Y. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.002 · Cited by 38
Notch Signaling and Liver Cancer
Kawaguchi, K., & Kaneko, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_6 · Cited by 39
GSAP regulates lipid homeostasis and mitochondrial function associated with Alzheimer’s disease
Xu, P., Chang, J. C., Zhou, X., Wang, W., Bamkole, M. A., Wong, E., Bettayeb, K., Jiang, L.-L., Huang, T. Y., Luo, W., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202446 · Cited by 39
Restoring Calcium Homeostasis to Treat Alzheimer’s Disease: A Future Perspective
Александровна, П. Е., Власова, О. Л., & Борисович, Б. И. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.36 · Cited by 39
De Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
“Ultimately this contributed to their failure in the clinic, largely due to unexpected adverse drug effects on the skin, the vascular and immune system, and cognition (Doody et al, 2013; Coric et al, 2015).”
BackgroundTherapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
“Blocking γ-secretase pathways (e.g., Tarenflurbil [23], Semagacestat [22], Avagacestat [155]) is another approach in decreasing APP proteolysis followed by Aβ production, but they were not able to improve cognitive functions of AD brains neither [23].”
BackgroundThe 5-Lipoxygenase as modulator of Alzheimer’s γ-secretase and therapeutic target
Chu, J., & Praticò, D. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.010 · Cited by 38
Choi, B., Kim, S., Jang, B.-G., & Kim, M.-J. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.02.024 · Cited by 35
Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase
Coyne, G. O., Woodring, T. S., Lee, C. R., Chen, A. P., & Kong, H. H. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.051 · Cited by 37
“on b Notably, the largest investigation of more than 1,500 patients randomized to treatment with GS inhibitor semagacestat (Doody et al., 2013) was terminated”
BackgroundFlotillin is a Novel Diagnostic Blood Marker of Alzheimer’s Disease
Abdullah, M., Kimura, N., Akatsu, H., Hashizume, Y., Taslima, F., Tachita, T., Iida, S., Zou, K., Matsubara, E., & Michikawa, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190908 · Cited by 36
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Caselli, R. J., Knopman, D. S., & Bu, G. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12124 · Cited by 38
MAM and C99, key players in the pathogenesis of Alzheimer’s disease
Pera, M., Montesinos, J., Larrea, D., Agrawal, R. R., VELASCO, K. R., Stavrovskaya, I. G., Yun, T. D., & Área-Gómez, E. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.016 · Cited by 37
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis
Lu, L., Zheng, X., Wang, S., Tang, C., Zhang, Y., Yao, G., Zeng, J., Ge, S., Wen, H., Xu, M., et al. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323497 · Cited by 40
Artificial intelligence for neurodegenerative experimental models
Marzi, S. J., Schilder, B. M., Nott, A., Frigerio, C. S., Willaime‐Morawek, S., Bucholc, M., Hanger, D. P., James, C., Lewis, P. A., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13479 · Cited by 35
“To improve reproducibility, and to allow the identification and further investigation of key background genetic modifiers of the dis-easephenotype,ideallysequencingshouldberepeatedafterextensive backcrossingbyacademiclaboratories,andifmicearebredtocongenic lines by commercial suppliers.”
BackgroundCurrent and Emerging Therapies for Alzheimer’s Disease
Nygaard, H. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.009 · Cited by 46
Rauth, S., Hinz, D., Borger, M. A., Uhrig, M., Mayhaus, M., Riemenschneider, M. J., & Skerra, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160114 · Cited by 39
Raven, F., Ward, J. F., Zoltowska, K. M., Wan, Y., Bylykbashi, E., Miller, S., Shen, X., Choi, S. H., Rynearson, K. D., Berezovska, O., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.08.028 · Cited by 37
“Although it decreased the levels of all Aβ species (Potter et al., 2013), semagacestat recently failed in the pivotal phase 3 clinical trial for AD (Doody et al., 2013).”
BackgroundA refined concept: α-synuclein dysregulation disease
Mochizuki, H., Choong, C., & Masliah, E. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.011 · Cited by 37
Optimizing poly ( ADP ‐ribose) polymerase inhibition through combined epigenetic and immunotherapy
Prasanna, T., Wu, F., Khanna, K. K., Yip, D., Malik, L., Dahlstrom, J. E., & Rao, S. (2018) · Cancer Science · doi:10.1111/cas.13799 · Cited by 37
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 38
New insights in drug development for Alzheimer's disease based on microglia function
Qiao, O., Ji, H., Zhang, Y., Zhang, X., Zhang, X., Liu, N., Huang, L., Liu, C., & Gao, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111703 · Cited by 35
Alzheimer’s disease progression by geographical region in a clinical trial setting
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu-Seifert, H., Grill, J. D., Doody, R. S., Aisen, P., Raman, R., Miller, D. S., Hake, A. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0127-0 · Cited by 35
“The study designs have been published previously [12,13,15,16].”
BackgroundMethodSelf-citationTurnquist, C., Wang, Y., Severson, D. T., Zhong, S., Sun, B., Ma, J., Constantinescu, S. N., Ansorge, O., Stolp, H. B., Molnár, Z., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407898111 · Cited by 35
“However, such treatment resulted in higher cancer incidence in a phase III clinical trial of Semagacestat (2).”
BackgroundTherapeutic Approaches to Alzheimer’s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection
Taliyan, R., Chandran, S. K., & Kakoty, V. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716101411 · Cited by 35
Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 40
Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 40
“In fact, a clinical trial of the g-secretase inhibitor LY450139 (Semagacestat) was discontinued because of the exacerbation of cognitive function and an increase in the incidence of skin cancer [Doody et al., 2013].”
BackgroundStem cells as a promising therapeutic approach for Alzheimer’s disease: a review
Fouad, G. I. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0078-x · Cited by 34
“However, several Aβ-targeting treatments failed to restore neurocognitive function (Coric et al. 2012; Doody et al. 2013; Kile et al. 2017).”
BackgroundDo anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
Panza, F., Lozupone, M., Bellomo, A., & Imbimbo, B. P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100948 · Cited by 37
New RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics
Riscado, M., Baptista, B., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091397 · Cited by 35
“Unfortunately, target toxicity is inevitable due to the approximately 40 cellular substrates of the γ-secretase, leading to the closure of the clinical trials [92,93].”
BackgroundAlzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Paniri, A., Hosseini, M. M., & Akhavan‐Niaki, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03626-y · Cited by 36
Relationship between Serum Levels of Tau Fragments and Clinical Progression of Alzheimer's Disease
Henriksen, K., Byrjalsen, I., Christiansen, C., & Karsdal, M. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140984 · Cited by 37
Hong, Z., Yu, S., Wang, Z., & Zhu, Y. Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818544 · Cited by 36
“Many previous studies have shown negative results in human clinical trials: (1) Semagacestat, a small-molecule γ-secretase inhibitor, significantly reduced Aβ40 and Aβ42 levels in AD patients’ brains, but failed to ameliorate patients’ cognitive impairment [3]; (2) Solanezumab, a monoclonal antibody that promoting Aβ…”
ResultLenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0371-6 · Cited by 34
New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
M. Wilkins, H., & K. Morris, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 35
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
“However, γ -secretases inhibitors were shown to exert important off-target effects (e.g., due to Notch signaling alteration) [190] and toxicity issues [191], causing the failure of clinical trials.”
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.